Throughout the study ( mean secukinumab exposure , @ days ; mean placebo exposure , @ days ) , four patients in the secukinumab groups had a stroke ( @ per @ patient-years ; @ % confidence interval -LSB- CI -RSB- , @ to @ ) , and two had a myocardial infarction ( @ per @ patient-years ; @ % CI , @ to @ ) , as compared with no patients in the placebo group .